Douglas Ward

Author PubWeight™ 6.67^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.	Clin Infect Dis	2007	1.17
2	Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.	AIDS	2007	1.01
3	ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.	HIV Clin Trials	2012	0.95
4	Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.	HIV Clin Trials	2011	0.93
5	Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.	HIV Clin Trials	2008	0.88
6	The effect of carbohydrate ingestion on plasma interleukin-6, hepcidin and iron concentrations following prolonged exercise.	Cytokine	2010	0.87
7	Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy.	J Acquir Immune Defic Syndr	2015	0.84
8	Virologic and immunologic activity of PegIntron in HIV disease.	AIDS	2009	0.75